Biochemistry and cell biology of endotoxins

International Journal of Occupational and Environmental Health

Volumn 3, Issue 1 SUPPL., 1997, Pages

  Ulmer, Artur J ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002954764     PISSN: 10773525     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (130)

1. Pfeiffer R. Untersuchungen über das Choleragift. Zf f Hygiene. 1892;11:393-412.
2. Nogare D. Southwestern Internal Medicine Conference: Septic Shock. Am J Med Sci. 1991;302:50-65.
3. Vogel SN. Hogan MM. Role of cytokines in endotoxin-mediated host responses. In Oppenheim JJ, Shevach EM (eds). Immunophysiology: The Role of Cells and Cytokines in Immunity and Inflammation. New York: Oxford University Press, 1990, pp 238-58.
4. Beutler B, Cerami A. The biology of cachectin/TNF. A primary mediator of the host response. Annu Rev Immunol. 1989;7: 625-55.
5. Dinarello CA. Interleukin-1. Rev Infect Dis. 1984,6:51-95.
6. Galanos C, Freudenberg MA, Katschinski T, Salomao R, Mossmann H, Kumazawa Y. Tumor necrosis factor and host response to endotoxin. In Ryan JL, Morrison DC (eds). Bacterial Endotoxic Lipopolysaccharides. Vol. II, Immunopharmacology and Pathophysiology. Boca Raton, FL, USA: CRC Press, 1992, pp 75-102.
7. Haziot A, Tsuberi B-Z, Goyert SM. Neutrophil CD14: biochemical properties and role in the secretion of tumor necrosis factor-α in response to lipopolysaccharide. J Immunol. 1994;150:5556-65.
8. Loppnow H. LPS, recIL1 and smooth muscle cell-IL1 activate vascular cells by specific mechanisms. In Levin J, Van Deventer SJH, Van der Poll T, and Sturk A (eds). Bacterial Endotoxins: Basic Science to Anti-sepsis Strategies. New York: Wiley-Liss, 1994, pp 309-21.
9. Mattern T, Thanhäuser A, Reiling N, et al. Endotoxin and lipid A stimulate proliferation of human T cels in the presence of autologous monocytes. J. Immunol. 1994;153:2996-3004.
10. Palam C, Cassone A, Serbousek D, Pearson CA, Djeu JY. Lactoferrin release and interleukin-1, interleukin-6, and tumor necrosis factor production by human polymorphonuclear cells stimulated by various lipopolysaccharides: relationship to growth inhibition of Candida albicans. Infect Immunol. 1992;60:4604-11.
11. Galanos C, Lüderitz O, Rietschel ETh, et al. Synthetic and natural Escherichia coli free lipid A express identical endotoxic activities. Eur J Biochem. 1985;148:1-5.
12. Imoto M, Yoshimura H, Shimamoto T, Sakaguchi N, Kusumoto S, Shiba T. Total synthesis of Escherichia coli lipid A, the endotoxically active principle of cell-surface lipopolysaccharide. Bull Chem Soc Jpn. 1987,60.2205-14.
13. Kusumoto S, Yamamoto M, Shiba T. Chemical synthesis of lipid X and lipid Y, acylglucosamine-1-phosphates isolated from Escherichia coli mutants. Tetrahedron Letter. 1984;25:3727-30.
14. Rietschel ETh, Brade L, Schade U, et al. Bacterial endotoxins: properties and structure of biologically active domains. In Schrinner E, Richmond MH, Seibert G, Schwarz U (eds). Surface of Microorganisms and Their Interactions with the Mammalian Host. Weinheim, Germany: Verlag Chemie, 1988, pp 1-41.
15. Feist W, Ulmer AJ, Musehold J, Brade H, Kusumoto S, Flad H-D. Induction of tumor necrosis factor-alpha release by lipopolysaccharide and defined lipopolysaccharide partial structures. Immunobiology. 1989;179:293-307.
16. Loppnow H, Brade L, Brade H, et al. Induction of human interleukin 1 by bacterial and synthetic lipid A. Eur J Immunol. 1986;16:1263-7.
17. Wang M-H, Flad H-D, Feist W, et al. Inhibition of endotoxin-induced interleukin 6 production by synthetic lipid A partial structures in human peripheral blood mononuclear cells. Infect Immunol. 1991;59.4655-64.
18. Rietschel ETh, Kirikae T, Feist W, et al. Molecular aspects of the chemistry and biology of endotoxin. In Sies H, Flohé L, Zimmer G (eds). Molecular Aspects of Inflammation (42. Colloquium Mosbach, 1991). Berlin, Germany: Springer Verlag, 1991, pp 207-31.
19. Kovach NL, Yee E, Munford RS, Raetz CRH, Harlan JM. Lipid IVa inhibits synthesis and release of tumor necrosis factor induced by lipopolysaccharide in human whole blood ex vivo. J Exp Med. 1990;172:77-84.
20. Homma JY, Matsuura M, Kumazawa Y. Structure-activity relationship of chemically synthesized nonreducing parts of lipid A analogs. Adv Exp Med Biol. 1990;256:101-19.
21. Saiki I, Maeda H, Murata J, et al. Production of interleukin I from human monocytes stimulated by synthetic lipid A subunit analogues. Int J Immunopharmacol. 1990;12:297-305.
22. Galanos C, Lehmann V, Lüderitz O, et al. Endotoxic properties of chemically synthesized lipid A part structures: comparison of synthetic lipid A precursor and synthetic analogues with biosynthetic lipid A precursor and free lipid A. Eur J Biochem. 1984;140: 221-7.
23. Golenbock DT, Hampton RY, Qureshi N, Takayama K, Raetz CRH. Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes. J Biol Chem. 1991;266:19490-8.
24. Kirikae T, Schade FU, Zähringer U, et al. The significance of the hydrophilic backbone and the hydrophobic fatty acid regions of lipid A on macrophage binding and cytokine induction. FEMS Immunol Med Microbiol. 1983;8:13-26.
25. Kirkland TN, Qureshi N, Takayama K. Diphosphoryl lipid A derived from lipopolysaccharide (LPS) from Rhodopseudomonas sphaeroides inhibits activation of 70Z/3 cells by LPS. Infect Immunol. 1991;59:131-6.
26. Freudenberg AM, Keppler D, Galanos C. Requirement for lipopolysaccharide-responsive macrophages in galactosamine-induced sensitization to endotoxin. Infect Immunol. 1996;51: 891-5.
27. Rietschel ETh, Kirikae T, Schade FU, et al. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J. 1994;8:217-25.
28. Munford RS, Hall CL. Purification of acyloxyacyl hydrolase, a leukocyte enzyme that removes secondary acyl chains from bacterial lipopolysaccharies. Biol Chem. 1989;264:15613-9.
29. Luchi M, Munford RS. Binding, internalization, and deacylation of bacterial lipopolysaccharide by human neutrophils. J Immunol. 1993;151:959-69.
30. Weiss J, Elsbach P, Olsson I, Odeberg H. Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. J Biol Chem. 1978;253:2664-72.
31. Marra MN, Wilde CG, Griffith JE, Snable JL, Scott RW. Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. J Immunol. 1990;144.622-6.
32. Weiss J, Elsbach P, Shu C, et al. Human bactericidal/permeability-increasing protein and a recombinant NHg-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit necrosis factor release induced by the bacteria. J Clin Invest. 1992,90:1122-30.
33. AndersonJ, Melchers F, Galanos C, Lüderitz O. The mitogenic effect of LPS on bone marrow derived mouse lymphocytes. Lipid A as the mitogenic part of the molecule. J Exp Med. 1973;137:943-53.
34. Milner ECB, Rudbach JA, VonEschen KB. Cellular responses to bacterial lipopolysaccharide: T cells recognize LPS determinants. Scand J Immunol. 1983;18:21-8.
35. Vogel SN, Hilfiker ML, Caulfield MJ. Endotoxin-induced T lymphocyte proliferation. J Immunol. 1983; 130:1774-9.
36. Baker PJ. Effect of endotoxin on suppressor T cell function. Immunobiology. 1993;187:372-81.
37. Pober JS, Cotran RS. The role of endothelial cells in inflammation. Transplantation. 1990;50:537-44.
38. Libby P, Loppnow H, Fleet JC, et al. Production of cytokines by vascular cells - an update and implications for atherogenesis. In Gotlieb AI, Langille BL, Federoff S (eds). First Altschul Symposium - Atherosclerosis: Cellular and Molecular Interactions in the Artery Wall. New York: Plenum Press, 1991, pp 161-9.
39. Camussi G, Mariano F, Biancone L, et al. Lipopolysaccharide binding protein and CD14 modulate the synthesis of platelet-activating factor by human monocytes and mesangial and endothelial cells stimulated with lipopolysaccharide. J Immunol. 1995;155:316-24.
40. Loppnow H, Libby P. Adult human vascular endothelial cells express the IL6 gene differentially in response to LPS or IL1. Cell Immunol. 1989;122:493-503.
41. Pugin J, Schürer-Maly C-C, Leturcq D, Moriarty A, Ulevitch RJ, Tobias PS. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci USA. 1993,90:2744-8.
42. Wright SD, Jong MTC. Adhesion-promoting receptors on human macrophages recognize E. coli by binding to lipopolysaccharide. J Exp Med. 1986;164:1876-88.
43. Detmers PA, Wright SD. Adhesion-promoting receptors on leukocytes. Curr Opin Immunol. 1988;1:10-5.
44. Ingalls RR, Golenbock DT. CD11c/CD 18, a transmembrane signaling receptor for lipopolysaccharide. J Exp Med. 1995;181: 1473-9.
45. Morrison DC. The case for specific lipopolysaccharide receptors expressed on mammalian cells. Microbial Pathogenesis. 1989; 7:389-98.
46. Kirikae T, Kirikae F, Schade UF, et al. Detection of lipopolysaccharide-binding proteins on membrane of murine lymphocyte and macrophage-like cell lines. FEMS Microbiol Immunol. 1991; 76:327-36.
47. Schutt C, Ringel B, Nausch M, et al. Human monocyte activation induced by an anti-CD14 monoclonal antibody. Immunol Lett. 1988;19:321-8.
48. 125I-LPS. Infect Immunol. 1992;60.5145-52.
49. Weidemann B, Brade H, Rietschel ETh, et al. Soluble peptidoglycan-induced monokine production can be blocked by anti-CD14 monoclonal antibodies and by lipid A partial structures. Infect Immunol. 1994,62:4709-15.
50. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990;249:1431-3.
51. Schuman RR, Leong SR, Flaggs GW, et al. Structure and function of lipopolysaccharide binding protein. Science. 1990;249:1429-31.
52. Tobias PS, Ulevitch RJ. Lipopolysaccharide binding protein and CD14 in LPS dependent macrophage activation. Immunobiology. 1993;187:227-32.
53. Wright SD, Ramos RA, Tatel M, Miller DS. Septin: a factor in plasma that opsonizes lipopolysaccharide-bearing particles for recognition by CD14 on phagocytes. J Exp Med. 1992;176:719-27.
54. Haziot A, Chen S, Ferrero E, Low MG, Silber R, Goyert SM. The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J Immunol. 1988; 141:547-52.
55. Lee JD, Kravchenko V, Kirkland TN, et al. Glycosyl-phosphatidylinositol-anchored or integral membrane forms of CD14 mediate identical cellular responses to endotoxin. Proc Natl Acad Sci USA, 1993;90.9930-4.
56. Lund-Johansen F, Olweus J, Symington FW, et al. Activation of human monocytes and granulocytes by monoclonal antibodies to glycosylphosphatidylinositol-anchored antigens. Eur J Immunol. 1993;23:2782-91.
57. Morrison DC, Lei M-G, Kirikae T, Chen T-Y. Endotoxin receptors on mammalian cells. Immunobiology 1993;187:212-26.
58. Golenbock DT, Hampton RY, Raetz CRH, Wright SD. Human phagocytes have multiple lipid A-binding sites. Infect Immunol. 1990;58:4069-75.
59. Haeffner-Cavaillon N, Cavaillon J-M. Involvement of the LPS receptor in the induction of interleukin-l in human monocytes stimulated with endotoxins. Ann Inst Pasteur Immunol. 1987; 138:473-7.
60. Tahri-Jouti M-A, Mondange M, Le Dur A, et al. Specific binding of lipopolysaccharides to mouse macrophages. II. Involvement of distinct lipid A substructures. Molec Immunol. 1990;27:763-70.
61. Bazil V, Horejsi V, Baudys M, et al. Biochemical characterization of a soluble form of the 53-kDa monocyte surface antigen. Eur J Immunol. 1986;16:1583-9.
62. Labeta MO, Durieux JJ, Fernandez N, Herrmann R, Ferrara P. Release from a human monocyte-like cell line of two different soluble forms of the lipopolysaccharide receptor, CD14. Eur J Immunol. 1993;23:2144-51.
63. SchletterJ, Brade H, Brade L, et al. Binding of lipopolysaccharide (LPS) to an 80 kD membrane protein of human cells is mediated by soluble CD14 and LPS-binding protein. Infect Immunol. 1995; 63:2576-80.
64. Feist W, Ulmer AJ, Wang M-H, et al. Modulation of lipopolysaccharide-induced production of tumor necrosis factor, interleukin 1, and interleukin 6 by synthetic precursor Ia of lipid A. FEMS Microbiol Immunol. 1992;89:73-90.
65. Loppnow H, Brade H, Duerrbaum I, et al. IL-1 induction capacity of defined lipopolysaccharide and partial structures. J Immunol. 1989;142:3229-38.
66. Wang M-H, Feist W, Herzbeck H, et al. Suppressive effect of lipid A partial structures on lipopolysaccharide or lipid A-induced release of interleukin 1 by human monocytes. FEMS Microbiol Immunol. 1990,64:179-86.
67. Wang M-H, Flad H-D, Feist W, et al. Inhibition of endotoxin or lipid A-induced tumor necrosis factor production by synthetic lipid A partial structures in human peripheral blood mononuclear cells. Lymphokine Cytokine Res. 1992;11:23-31.
68. Heine H, Ulmer AJ, Flad H-D, Hauschildt S. LPS-induced change of phosphorylation of two cytosolic proteins in human monocytes is prevented by inhibitors of ADP-ribosylation. J Immunol. 1995; 155:4899-908.
69. Takayama K, Quereshi N, Beutler B, Kirkland ThN. Diphosphoryl lipid A from Rhodopseudomonas sphaeroides ATCC 17023 blocks induction of cachectin in macrophages by lipopolysaccharide. Infect Immunol. 1989;57:1336-8.
70. Loppnow H, Libby P, Freudenberg M, Kraus JH, Weckesser J, Mayer H. Cytokine induction by lipopolysaccharide (LPS) corresponds to the lethal toxicity and is inhibited by nontoxic Rhodobacter capsulatus LPS. Infect Immunol. 1990;58:3743-50.
71. Christ WJ, Asano O, Robidoux ALC, et al. E5531, a pure endotoxin antagonist of high potency. Science. 1995;268:80-3.
72. Heine H, Brade H, Kusumoto S. et al. Inhibition of LPS-binding on human monocytes by phosphonooxyethyl analogs of lipid A. J Endotox Res. 1994;1:14-20.
73. Lauener RP, Geha RS, Vercelli D. Engagement of the monocyte surface antigen CDH induces lymphocytic function-asociated antigen-1/intercellular adhesion molecule 1-dependent homotypic adhesion. J Immunol. 1990;145:1390-8.
74. Heumann D, Barras C, Severin A, Glauser MP, Tomasz A. Gram-positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes. Infect Immunol. 1994,62:2715-21.
75. Pugin J, Heumann D, Tomasz A, et al. CD14 is a pattern recognition receptor. Immunity. 1994;1:509-16.
76. Marra MN, Wilde CG, Collins MS, Snable JL, Thornton MB, Scott RW. The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin. J Immunol. 1992;148: 532-7.
77. Mannion BA, Kalatzs ES, Weiss, J, Elsbach P. Preferential binding of the neutrophil granule-derived bactericidal/permeability-increasing protein to target bacteria. J Immunol. 1989;142: 2807-12.
78. Weiss J, Muello K, Victor M, Elsbach P. The role of lipopolysaccharides in the action of the bactericidal/permeability-increasing protein to target bacteria. J Immunol. 1984;132:3109-15.
79. Tobias PS, Mathison JC, Ulevitch RJ. A family of lipopolysaccharide binding proteins involved in responses to gram-negative sepsis. J Biol Chem. 1988;263:13479-81.
80. Gazzano-Santoro H, Parent JB, Grinna L, et al. High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. Infect Immunol. 1992;60:4754-61.
81. Tobias PS, Soldau K, Ulevitch RJ. Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein. J Biol Chem. 1989,264:10867-71.
82. 23. Infect Immunol. 1995;63:2201-5.
83. Mathison JC, Tobias PS, Wolfson E. Ulevitch RJ. Plasma lipopolysaccharide (LPS)-binding protein. A key component in macrophage recognition of gram-negative LPS. J Immunol. 1992; 149:200-6.
84. Heumann D, Galla y P, Betz-Corradin S, Barras C, Baumgartner JD, Glauser M-P. Competition between bactericidal/permeability-increasing protein and lipopolysaccharide-binding protein for lipopolysaccharide binding to monocytes. J Infect Dis. 1993; 167:1351-7.
85. Dentener MA, von Asmuth EJU, Francot GJM, Marra MN, Buurman WA. Antagonistic effects of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein on lipopolysaccharide-induced cytokine release by mononuclear phagocytes. J Immunol. 1993;151:4258-65.
86. Fisher CJ, Marra MN, Palardy JE, Marchbanks CR, Scott RW, Opal SM. Human neutrophil bactericidal/permeability-increasing protein reduces mortality rate from endotoxin challenge: a placebo-controlled study. Crit Care Med. 1994;22:553-8.
87. Jin H, Yang R, Marsters S, et al. Protection against endotoxic shock by bactericidal/permeability-increasing protein in rats. J Clin Invest. 1995;95:1947-52.
88. Haziot A, Rong GW, Lin X-Y, SilverJ, Goyert SM. Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J Immunol. 1994; 154:6529-32.
89. Schutt C, Schilling T, Grunwald U, Schönfeld W, Krüger C. Endotoxin-neutralizing capacity of soluble CD14. Res Immunol. 1992;143:71-8.
90. Rietschel ETh, Brade H, Holst O, et al. Bacterial endotoxin: chemical constitution, biological recognition, host response and immunological detoxification. Curr Topics Microbiol Immunol. 1996;216:39-81.
91. Di Padova FE, Brade H, Barclay R, et al. A broadly cross-protecthe monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides. Infect Immunol. 1993,61:3863-72.
92. Di Padova FE, Mikol V, Barclay GR, Poxton IR, Brade H, Rietschel ETh. Anti-lipopolysaccharide core antibodies. Progr Clin Biol Res. 1994;388:85-94.
93. Di Padova FE, Gram H, Barclay R, Poxton I, Liehl E, Rietschel ETh. Monoclonal antibodies to endotoxin core as a new approach in endotoxemia therapy. In Morrison DC, Ryan JL (eds). Novel Therapeutic Strategies in the Treatment of Sepsis. New York: Marcel Dekker, 1995, pp 13-31.
94. Galanos C, Freudenberg MA, Jay F, et al. Immunogenic properdes of lipid A. Rev Infect Dis. 1984;6:546-52.
95. Rietschel ETh, Galanos C. Lipid A antiserum-mediated protection against lipopolysaccharide and lipid A-induced fever and skin necrosis. Infect Immunol. 1977;15:34-19.
96. Fujihara Y, Lei M-G, Morrison DC. Characterization of specific binding of a human immunoglobulin M monoclonal antibody to lipopolysaccharide and its lipid A domain. Infect Immunol. 1993;61:910-8.
97. Teng NNH, Kaplan HS, Herbert JM, et al. Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc Nad Acad Sci USA. 1985;82:1790-4.
98. Young LS, Gascon R, Alam S, Bermudez LEM. Monoclonal antibodies for treatment of gram-negathe infections. Rev Infect Dis. 1989;11:1564-71.
99. Baumgartner J-D, Glauser M-P. Immunotherapy of endotoxemia and septicemia. Immunobiology. 1993;187:464-77.
100. Wenzel R, Bone R, Fein A, et al. Results of a second double-blind, randomized, controlled trial of antiendotoxin antibody E5 in gram-negative sepsis (abstr). Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 19 to Oct 2, 1991, Am Soc Microbiol, p 294.
101. Bhat NM, Bieber MM, Chapman CJ, Stevenson FK, Teng NNH. Human antilipid A monoclonal antibodies bind to human B cells and the i antigen on cord red blood cells. J Immunol. 1993;151:5011-21.
102. Greisman SE, Woodwar WE. Mechanisms of endotoxin tolerance. III. The refractory state during continuous intravenous infusions of endotoxin. J Exp Med. 1965;121:911-33.
103. Ziegler-Heitbrock HWL. Molecular mechanism in tolerance to lipopolysaccharide. J Inflamm. 1995;45:13-26.
104. Freudenberg MA, Galanos C. Induction of tolerance to lipopolysaccharide (LPS)-D-galactosamine lethality by pretreatment with LPS is mediated by macrophages. Infect Immunol. 1988;56:1352-7.
105. Mathison JC, Virca GD, Wolfson E, Tobias PS, Glaser K, Ulevitch RJ. Adaptation to bacterial lipopolysaccharide controls lipopolysaccharide-induced tumor necrosis factor production in rabbit macrophages. J Clin Invest. 1990,85:1108-18.
106. Matic M, Simon SR. Tumor necrosis factor release from lipopolysaccharide-stimulated human monocytes: lipopolysaccharide tolerance in vitro. Cytokine. 1991;3:576-83.
107. Haas JG, Bauerle PA, Riethmüller G, Ziegler-Heitbrock HWL. Molecular mechanisms in down-regulation of tumor necrosis factor expression. Proc Natl Acad Sci USA. 1990;87:9563-7.
108. Ziegler-Heitbrock HWL, Blumenstein M, Käfferlein E, et al. In vitro desensitization to lipopolysaccharide suppresses tumor necrosis factor, interleukin-1 and interleukin-6 gene expression in a similar fashion. Immunology. 1992;75:264-8.
109. Fraker DL, Stovroff MC, Merino MJ, Norton JA. Tolerance to tumor necrosis factor in rats and the relationship to endotoxin tolerance and toxicity. J Exp Med. 1988;168.95-105.
110. Wallach D, Holtmann H, Engelmann H, Nophas Y. Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1. J Immunol. 1988;140.2994-9.
111. 51C-labeled lipid A before and after the induction of endotoxin tolerance. Proc Natl Acad Sci USA. 1984;81:3491-5.
112. Fahmi H. Chaby R. Desensitization of macrophages to endotoxin effects is not correlated with a down-regulation of lipopolysaccharide-binding sites. Cell Immunol. 1993;150:219-29.
113. Labeta MO, Durieux J-J, Spagnoli G, Fernandez N, Wijdenes J, Herrmann R. CD14 and tolerance to lipopolysaccharide: biochemical and functional analysis. Immunology. 1993,80.415-23.
114. Mathison J, Wolfson E, Steinmann S, Tobias P, Ulevitch R. Lipopolysaccharide (LPS) recognition in macrophages. J Clin Invest. 1993,92.2053-9.
115. Takasuka N, Matsuura K, Yamamoto S, Akagawa KS. Suppression of TNF-α mRNA expression in LPS-primed macrophages occurs at the level of nuclear factor-kappa B activation, but not at the level of protein kinase C or CD14 expression. J Immunol. 1995;154:4803-12.
116. Ziegler-Heitbrock HWL, Wedel A, Schraut W, et al. Tolerance to lipopolysaccharide involves mobilization of nuclear factor kappa B with predominance of p50 homodimers. J Biol Chem. 1994;269.17001-4.
117. Frankenberger M, Pechumer H, Ziegler-Heitbrock HWL. Interleukin-10 is upregulated in LPS tolerance. Circulatory Shock. 1995;45:56-63.
118. Henricson BE, Manthey CL, Perera PY, Hamilton TA, Vogel SN. Dissociation of lipopolysacharide (LPS)-inducible gene expression in murine macrophages pretreated with smooth LPS versus monophosphoryl lipid A. Infect Immunol. 1993;61:2325-33.
119. Randow F, Syrbe C, Meisel C, et al. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor β. J Exp Med. 1995;181:1887-92.
120. Amano Y, Lee SW, Allison AG. Inhibition by glucocorticoids of the formation of interleukin-1α, interleukin-1β, and interleukin 6: mediation by decreases mRNA stability. Mo Pharmacol. 1992;43:176-82.
121. Barber AE, Coyle SM, Marano MA, et al. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol. 1993;150:1999-2006.
122. Beutler B, Krochin N, Milsark IW, Luedke C, Cerami A. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science. 1986;232:977-9.
123. Bemelmans MHA, Gouma DJ, Buurman WA. Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J Immunol. 1993;150:2007-17.
124. Henricson BE, Neta R, Vogel SN. An interleukin-1 receptor antagonist blocks lipopolysaccharide-induced colony-stimulating factor production and early endotoxin tolerance. Infect Immunol. 1991;59:1188-91.
125. Neuner P, Klosner G. Pourmojib M, Trautinger F, Knobler R. Selective release of tumor necrosis factor binding protein II by malignant human epidermal cells reveals protection from tumor necrosis factor alpha-mediated cytotoxicity. Cancer Res. 1994; 54:6001-5.
126. Schade FU, Franke C, Schlegel J, Rietschel ETh. Formation of a TNF synthesis inhibitor in endotoxin tolerance. In Levin J, Alving CR, Munford RS, Redl H (eds). Bacterial Endotoxins: Lipopolysaccharide from Genes to Therapy. New York: Wiley-Liss, 1995, pp 513-522.
127. Greisman SE, Young EJ, Carozza FAJ. Mechanisms of endotoxin tolerance. V. Specificity of the early and the late phases of pyrogenic tolerance. J Immunol. 1969;103:1223-36.
128. Mackensen A, Galanos C, Engelhardt R. Modulating activity of interferon-γ on endotoxin-induced cytokine production in cancer patients. Blood. 1991;78:3254-8.
129. Mackensen A, Galanos C, Wehr U, Engelhardt R. Endotoxin tolerance: regulation of cytokine production and cellular changes in response to endotoxin application in cancer patients. Eur Cytok Netw. 1992;3:571-9.
130. Munoz C, Carlet J, Fitting C, Bisset B, Blériot J-P, Cavaillon J-M. Deregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest. 1991;88:1747-54.